In a groundbreaking feat for clinical research and public health, global pharmaceutical leader Lupin Limited has set a new record by onboarding the highest number of diabetes patients in a Real-World Evidence (RWE) study, marking a milestone in the fight against one of the world’s most widespread chronic diseases.
The study, titled “Diabetes 360: Real Lives, Real Data”, has successfully enrolled over 1 million patients across India, making it the largest real-world diabetes study ever conducted by a single pharmaceutical company. The initiative aims to understand the lived experiences of diabetic patients outside of clinical trial settings — including medication adherence, lifestyle patterns, glycemic control, and co-morbidities.
“This record is not just about numbers — it’s about impact,” said Nilesh Gupta, Managing Director of Lupin. “Through this initiative, we are listening to patients at scale, gathering insights that will help shape more personalized, accessible, and effective diabetes care in the real world.”
Unlike traditional clinical trials, which operate under highly controlled conditions, real-world evidence studies observe patients in everyday settings. This approach allows researchers to assess how treatments perform in practical use, offering richer insights into long-term outcomes, challenges, and gaps in diabetes management.
The massive study spans urban and rural regions and integrates data from clinics, hospitals, and digital health platforms. Lupin collaborated with over 10,000 doctors and healthcare professionals, ensuring diverse representation across demographics, geographies, and treatment regimens.
Dr. Meera Joshi, one of the principal investigators of the study, emphasized its value: “This scale of patient participation gives us a comprehensive view of India’s diabetes landscape. The findings will help clinicians make better decisions, and policymakers create more responsive health programs.”
The achievement has been recognized by the Guinness World Records as the “Largest Real-World Diabetes Patient Enrollment by a Pharmaceutical Company”, placing Lupin at the forefront of patient-centric innovation in healthcare.
The preliminary results of the study are expected to be published later this year and are anticipated to influence not just diabetes treatment strategies in India, but also global best practices.
As diabetes continues to rise globally, Lupin’s initiative is being hailed as a bold step forward — proving that data, when drawn from real life, can help drive real change.
